Genetic Polymorphism and OROS-Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder(ADHD)
- Conditions
- Attention Deficit Hyperactivity Disorder
- Registration Number
- NCT00842127
- Lead Sponsor
- Bundang CHA Hospital
- Brief Summary
The purpose of this study is to examine whether genetic polymorphisms in drug transporters were associated with the side effects of OROS-methylphenidate medication in attention deficit/hyperactivity disorder(ADHD).
- Detailed Description
20 to 30% of children with attention deficit/hyperactivity disorder(ADHD) do not respond or could not tolerate methylphenidate treatment. Drug transporters such as multidrug resistant proteins(MDR) plays important role in the clearance of psychotropic drugs and their metabolites from brain tissue. It suggested that methylphenidate was a P-glycoprotein(encoded by MDR1 gene)substrate and showed inhibitory effects on the P-glycoprotein efflux function. Single nucleotide polymorphisms(SNP)in the MDR1 gene were analyzed in children and adolescents with OROS-methylphenidate treatment. The hypothesis is that MDR1(ABCB1) polymorphisms are associated with the side effects of OROS-methylphenidate.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 150
- ADHD
- Must be able to swallow a capsule
- Pervasive developmental disorder
- Mental retardation
- Psychotic disorder
- Bipolar disorder
- Suicidality
- Neurological disorder
- Concurrent psychiatric treatment
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Barkley side effects rating scale weeks 1, 2,4,8
- Secondary Outcome Measures
Name Time Method ADHD rating scale-Korean version; Clinical Global Impressions (CGI) of Severity and Improvement (CGI-S and CGI-I) 8 weeks
Trial Locations
- Locations (1)
Bundang CHA hospital
🇰🇷Seongnam, Kyonggi-do, Korea, Republic of